Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate

B L Zuraw, M Cicardi, H J Longhurst, J A Bernstein, H H Li, M Magerl, I Martinez-Saguer, S M M Rehman, P Staubach, H Feuersenger, R Parasrampuria, J Sidhu, J Edelman, T Craig, B L Zuraw, M Cicardi, H J Longhurst, J A Bernstein, H H Li, M Magerl, I Martinez-Saguer, S M M Rehman, P Staubach, H Feuersenger, R Parasrampuria, J Sidhu, J Edelman, T Craig

Abstract

Background: Hereditary angioedema (HAE) due to C1 inhibitor deficiency manifests as recurrent swelling attacks that can be disabling and sometimes fatal. Long-term prophylaxis with twice-weekly intravenous injections of plasma-derived C1-inhibitor (pdC1-INH) has been established as an effective treatment. Subcutaneous (SC) administration of pdC1-INH has not been studied in patients with HAE.

Methods: This open-label, dose-ranging, crossover study (COMPACT Phase II) was conducted in 18 patients with type I or II HAE who received two of twice-weekly 1500, 3000, or 6000 IU SC doses of highly concentrated volume-reduced CSL830 for 4 weeks each. The mean trough plasma levels of C1-INH functional activity, C1-INH and C4 antigen levels during Week 4, and overall safety and tolerability were evaluated. The primary outcome was model-derived steady-state trough C1-INH functional activity.

Results: After SC CSL830 administration, a dose-dependent increase in trough functional C1-INH activity was observed. C1-INH and C4 levels both increased. The two highest dose groups (3000 and 6000 IU) achieved constant C1-INH activity levels above 40% values, a threshold that was assumed to provide clinical protection against angioedema attacks. Compared with intravenous injection, pdC1-INH SC injection with CSL830 showed a lower peak-to-trough ratio and more consistent exposures. All doses were well tolerated. Mild-to-moderate local site reactions were noted with pain and swelling being the most common adverse event.

Conclusions: Subcutaneous volume-reduced CSL830 was well tolerated and led to a dose-dependent increase in physiologically relevant functional C1-INH plasma levels. A clinical outcome study of SC CSL830 in patients with HAE warrants further investigation.

Keywords: Berinert; C1-esterase inhibitor; hereditary angioedema; long-term prophylaxis; subcutaneous treatment.

© 2015 The Authors. Allergy Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Study schema. (A) Dosing scheme and sample collection during the study, (B)  = single dose of IV C1‐INH;  = single dose of subcutaneous (SC) CSL830;  = assessment of C1‐INH functional activity and plasma C1‐INH and C4 antigen concentrations;  = additional assessments of plasma C1‐INH functional activity.
Figure 2
Figure 2
Pharmacokinetic (PK) results. Modeled steady‐state trough C1‐INH functional activity (primary endpoint; red rectangles) and as‐observed C1‐INH functional activity (black triangles). Data points show the mean and 95% CI.
Figure 3
Figure 3
Final population pharmacokinetic (PK) model of as‐observed C1‐INH functional activity vs individual predictions of C1‐INH functional activity. The line of identity (solid red) is included as a reference.
Figure 4
Figure 4
Modeled biweekly C1‐INH functional activity after IV administration of (A) a therapeutic dose of 1000 IU pdC1‐INH concentrate, or subcutaneous (SC) administration of (B) 1500 IU, (C) 3000 IU, or (D) 6000 IU of CSL830. Median functional activity (solid lines), 5th and 95th percentiles (shaded areas) and 40% C1‐INH functional activity (dashed black line) are shown.

References

    1. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976;84:580–593.
    1. Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982;284:2–9.
    1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008;359:1027–1036.
    1. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1‐INH deficiency. J Allergy Clin Immunol 2012;130:692–697.
    1. Zuraw BL, Banerji A, Bernstein JA, Busse PJ, Christiansen SC, Davis‐Lorton M et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2013;1:458–467.
    1. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24–36.
    1. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H et al. Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67:147–157.
    1. Craig T, Aygören‐Pürsün E, Bork K, Bowen T, Boysen H, Farkas H et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012;5:182–199.
    1. Lang DM, Aberer W, Bernstein JA, Chng HH, Grumach AS, Hide M et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 2012;109:395–402.
    1. Zuraw BL, Bernstein JA, Lang DM, Craig T, Dreyfus D, Hsieh F et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin‐converting enzyme inhibitor‐associated angioedema. J Allergy Clin Immunol 2013;131:1491–1493.
    1. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014;69:602–616.
    1. Zuraw BL, Busse PJK, White M, Jacobs J, Lumry W, Baker J et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513–522.
    1. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor‐heated C1 inhibitor concentrate. N Engl J Med 1996;334:1630–1634.
    1. Wagenaar‐Bos IG, Drouet C, Aygören‐Pursun E, Bork K, Bucher C, Bygum A et al. Functional C1‐inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods 2008;338:14–20.
    1. Kelemen Z, Moldovan D, Mihaly E, Visy B, Szeplaki G, Csuka D et al. Baseline level of functional C1‐inhibitor correlates with disease severity scores in hereditary angioedema. Clin Immunol 2010;134:354–358.
    1. Späth PJ, Wüthrich B, Bütler R. Quantification of C1‐inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema‐evidence of a functionally critical level of C1‐inhibitor concentration. Complement 1984;1:147–159.
    1. Martinez‐Saguer I, Cicardi M, Suffritti C, Rusicke E, Aygören‐Pürsün E, Stoll H et al. Pharmacokinetics of plasma‐derived C1‐esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion 2014;54:1552–1561.
    1. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012;32:902–909.
    1. Kalaria S, Craig T. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc 2013;34:519–522.
    1. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006;26:653–668.
    1. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21‐month prospective study in a cohort of 103 patients. Allergy 2011;66:192–196.
    1. Frank MM. Update on preventive therapy (prophylaxis) for hereditary angioedema. Immunol Allergy Clin North Am 2013;33:495–503.
    1. Xu YY, Buyantseva LV, Agarwal NS, Olivieri K, Zhi YX, Craig TJ. Update on treatment of hereditary angioedema. Clin Exp Allergy 2013;43:395–405.
    1. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long‐term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153–161.
    1. Füst G, Farkas H, Csuka D, Varga L, Bork K. Long‐term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2011;41:256–262.
    1. Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 2012;14:559–570.
    1. McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther 2010;12:461–470.
    1. Quastel M, Harrison R, Cicardi M, Alper CA, Rosen FS. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983;71:1041–1046.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다